FDA Attempting To Overcome Major Roadblocks in Monitoring Drug Safety
Open Access
- 15 June 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 97 (12) , 872-873
- https://doi.org/10.1093/jnci/97.12.872
Abstract
The voluntary manufacturer withdrawal of the COX-2 inhibitor Vioxx (rofecoxib) last fall prompted many critics to question why the agency charged with ensuring the safety of pharmaceuticals—the U.S. Food and Drug Administration—did not lead the effort to issue warnings or remove the drug from the market.Keywords
This publication has 0 references indexed in Scilit: